Chia B L
Curr Med Res Opin. 1980;7(2):85-90. doi: 10.1185/03007998009112031.
The efficacy of metoprolol as an antihypertensive agent was assessed in 20 previously untreated Asian patients with mild to moderate hypertension. After a 4-week run-in period when placebo therapy was given, the patients were given oral metoprolol at a starting dosage of 100 mg twice daily. The dosage of metoprolol was increased at fortnightly intervals until either satisfactory blood pressure control, defined as a diastolic blood pressure of less than 90 mmHg or a greater than 10% fall in pre-treatment diastolic blood pressure, was achieved or a total of 400 mg metoprolol was reached. All 20 patients had satisfactory control of their blood pressures on a twice-daily regimen and the average dosage of metoprolol required was 200 mg daily. For the second part of the study, the medication was changed to a once-daily regimen at the same total dosage of metoprolol. Final efficacy of once-daily therapy was assessed after 8 weeks of treatment. All blood pressure and pulse rate reductions were significant (P < 0.001) from the placebo phase. However, twice-daily and once-daily readings were not significantly different from each other. No side-effects were reported during the study.
在20名之前未接受过治疗的轻度至中度高血压亚洲患者中评估了美托洛尔作为抗高血压药物的疗效。在给予安慰剂治疗的4周导入期后，患者开始口服美托洛尔，起始剂量为每日两次，每次100mg。美托洛尔的剂量每两周增加一次，直至达到满意的血压控制，即舒张压低于90mmHg或治疗前舒张压下降超过10%，或美托洛尔总量达到400mg。所有20名患者每日两次服药方案的血压均得到满意控制，所需美托洛尔的平均剂量为每日200mg。在研究的第二部分，药物改为相同美托洛尔总剂量的每日一次服药方案。治疗8周后评估每日一次治疗的最终疗效。与安慰剂阶段相比，所有血压和脉搏率的降低均具有显著性（P<0.001）。然而，每日两次和每日一次的读数之间没有显著差异。研究期间未报告副作用。
